Restricted accessLetterFirst published online 2019-11
Re: “Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week,Placebo-Controlled,Fixed-Dose Trial” by Findling et al. (J Child Adolesc Psychopharmacol 2019;29:80–89)
FindlingRL, AdlerLA, SpencerTJ, GoldmanR, HopkinsSC, KoblanKS, KentJ, HsuJ, LoebelA: Dasotraline in children with attention-deficit/hyperactivity disorder: A six-week, placebo-controlled, fixed-dose trial. J Child Adolesc Psychopharmacol, 29:80–89, 2019.
2.
MosholderAD, GelperinK, HammadTA, PhelanK, Johann-LiangR: Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics, 123:611–616, 2009.
3.
ReeveS, SheavesB, FreemanD: The role of sleep dysfunction in the occurrence of delusions and hallucinations: A systematic review. Clin Psychol Rev, 42:96–115, 2015.
